Effects of NSAIDs on beagle crevicular cyclooxygenase metabolites and periodontal bone loss
This investigation focuses on the changes in the concentrations of cyclooxygenase (CO) products present within the crevicular fluid in naturally‐progressing periodontitis in the beagle and the effects of various non‐steroidal anti‐inflammatory drugs (NSAIDs) on these metabolite levels and disease pr...
Gespeichert in:
Veröffentlicht in: | Journal of periodontal research 1992-05, Vol.27 (3), p.207-213 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 213 |
---|---|
container_issue | 3 |
container_start_page | 207 |
container_title | Journal of periodontal research |
container_volume | 27 |
creator | Offenbacher, S. Williams, R. C. Jeffcoat, M. K. Howell, T. H. Odle, B. M. Smith, M. A. Hall, C. M. Johnson, H. G. Goldhaber, P. |
description | This investigation focuses on the changes in the concentrations of cyclooxygenase (CO) products present within the crevicular fluid in naturally‐progressing periodontitis in the beagle and the effects of various non‐steroidal anti‐inflammatory drugs (NSAIDs) on these metabolite levels and disease progression. Six groups of 5–6 beagles with periodontitis were followed for 6 months to determine the pretreatment rate of radiographic bone loss. At baseline, groups of animals were placed on soft chow to promote disease progression. Groups were treated with either placebo, three different formulations of systemic ibuprofen, systemic naproxen or topical flurbiprofen. During the 6‐month treatment phase, crevicular fluid (CF) samples and radiographs were taken at regular intervals. Radioimmunoassay of CF samples from untreated animals demonstrated a steady increase in prostaglandin E2 (PGE 2) over baseline values. At 1 month, CF‐PGE2 levels increased 2‐fold over baseline and, by 6 months, had reached a 5‐ to 6‐fold elevation. Crevicular fluid thromboxane B2 (CF‐TxB2) levels rapidly reached a 4‐ to 5‐fold peak over baseline at 1 month and subsequently dropped to a 2‐fold elevation for the remainder of the study. The rate of bone loss (BLOSS) in untreated animals increased 38% during the 6‐month period, as compared to baseline pretreatment BLOSS rates. Overall, there was a significant depression in the CF levels of both PGE2 and TxB2 in all NSAID‐treated groups. All NSAID treatments significantly retarded BLOSS, ranging from 21.0–36.9% of the control BLOSS rate. The topical application of flurbiprofen was as effective in depressing CF levels of PGE2 and TxB2 as systemic or sustained release formulations of other NSAIDs. The data further substantiate the concept that much of the BLOSS that occurs in periodontal disease is mediated by products of the cyclooxygenase pathway. Furthermore, CO activation represents a major regulatory step in bone destruction and may thereby serve as an important site for pharmacological modulation. |
doi_str_mv | 10.1111/j.1600-0765.1992.tb01670.x |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72996984</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72996984</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5027-70cb0daaec2dd48de79c5865a843a115c3eeced9d4cba0105895f4b8be604f563</originalsourceid><addsrcrecordid>eNqVkF1v0zAUhi0EGqXwE5AshLhLcOLYjrlAGlsZm6bxrSFxYfnjZErnxsVOof33uEpVrvGNbZ33POfoQehFRcoqn9fLsuKEFERwVlZS1uVoSMUFKbcP0OxYeohmhNR1QZu2eYyepLQk-c-FPEEnOdQS2szQz0XXgR0TDh2--Xp6eZ5fAzag7zxgG-F3bzdeR2x31oew3d3BoBPgFYzaBN-PkLAeHF5D7IMLw6g9NmEA7ENKT9GjTvsEzw73HH1_v_h29qG4_nhxeXZ6XVhGalEIYg1xWoOtnWtaB0Ja1nKm24bqqmKWAlhw0jXWaFIR1krWNaY1wEnTMU7n6NXEXcfwawNpVKs-WfBeDxA2SYlaSi4zbY7eTEEb83oROrWO_UrHnaqI2ptVS7XXp_b61N6sOphV29z8_DBlY1bg_rVOKnP95aGuk9W-i3qwfTrGGOVNRuXY2yn2p_ew-48F1NWXRU1EBhQToE8jbI8AHe8VF1QwdXtzoT5_uqI_3tFzdUv_AlGmpcc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72996984</pqid></control><display><type>article</type><title>Effects of NSAIDs on beagle crevicular cyclooxygenase metabolites and periodontal bone loss</title><source>Wiley-Blackwell Journals</source><source>MEDLINE</source><creator>Offenbacher, S. ; Williams, R. C. ; Jeffcoat, M. K. ; Howell, T. H. ; Odle, B. M. ; Smith, M. A. ; Hall, C. M. ; Johnson, H. G. ; Goldhaber, P.</creator><creatorcontrib>Offenbacher, S. ; Williams, R. C. ; Jeffcoat, M. K. ; Howell, T. H. ; Odle, B. M. ; Smith, M. A. ; Hall, C. M. ; Johnson, H. G. ; Goldhaber, P.</creatorcontrib><description>This investigation focuses on the changes in the concentrations of cyclooxygenase (CO) products present within the crevicular fluid in naturally‐progressing periodontitis in the beagle and the effects of various non‐steroidal anti‐inflammatory drugs (NSAIDs) on these metabolite levels and disease progression. Six groups of 5–6 beagles with periodontitis were followed for 6 months to determine the pretreatment rate of radiographic bone loss. At baseline, groups of animals were placed on soft chow to promote disease progression. Groups were treated with either placebo, three different formulations of systemic ibuprofen, systemic naproxen or topical flurbiprofen. During the 6‐month treatment phase, crevicular fluid (CF) samples and radiographs were taken at regular intervals. Radioimmunoassay of CF samples from untreated animals demonstrated a steady increase in prostaglandin E2 (PGE 2) over baseline values. At 1 month, CF‐PGE2 levels increased 2‐fold over baseline and, by 6 months, had reached a 5‐ to 6‐fold elevation. Crevicular fluid thromboxane B2 (CF‐TxB2) levels rapidly reached a 4‐ to 5‐fold peak over baseline at 1 month and subsequently dropped to a 2‐fold elevation for the remainder of the study. The rate of bone loss (BLOSS) in untreated animals increased 38% during the 6‐month period, as compared to baseline pretreatment BLOSS rates. Overall, there was a significant depression in the CF levels of both PGE2 and TxB2 in all NSAID‐treated groups. All NSAID treatments significantly retarded BLOSS, ranging from 21.0–36.9% of the control BLOSS rate. The topical application of flurbiprofen was as effective in depressing CF levels of PGE2 and TxB2 as systemic or sustained release formulations of other NSAIDs. The data further substantiate the concept that much of the BLOSS that occurs in periodontal disease is mediated by products of the cyclooxygenase pathway. Furthermore, CO activation represents a major regulatory step in bone destruction and may thereby serve as an important site for pharmacological modulation.</description><identifier>ISSN: 0022-3484</identifier><identifier>EISSN: 1600-0765</identifier><identifier>DOI: 10.1111/j.1600-0765.1992.tb01670.x</identifier><identifier>PMID: 1608034</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Administration, Oral ; Administration, Topical ; Alveolar Bone Loss - drug therapy ; Alveolar Bone Loss - metabolism ; Analysis of Variance ; Animals ; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage ; Anti-Inflammatory Agents, Non-Steroidal - pharmacology ; Biological and medical sciences ; bone loss ; Bones, joints and connective tissue. Antiinflammatory agents ; Cyclooxygenase Inhibitors - pharmacology ; cyclooxygenase metabolites ; Dentistry ; Dinoprostone - metabolism ; Dogs ; Flurbiprofen - administration & dosage ; Flurbiprofen - pharmacology ; Gingival Crevicular Fluid - chemistry ; Ibuprofen - administration & dosage ; Ibuprofen - pharmacology ; Medical sciences ; Naproxen - administration & dosage ; Naproxen - pharmacology ; NSAIDs ; Pharmacology. Drug treatments ; Prostaglandins F - metabolism ; Thromboxane B2 - metabolism</subject><ispartof>Journal of periodontal research, 1992-05, Vol.27 (3), p.207-213</ispartof><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5027-70cb0daaec2dd48de79c5865a843a115c3eeced9d4cba0105895f4b8be604f563</citedby><cites>FETCH-LOGICAL-c5027-70cb0daaec2dd48de79c5865a843a115c3eeced9d4cba0105895f4b8be604f563</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1600-0765.1992.tb01670.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1600-0765.1992.tb01670.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27915,27916,45565,45566</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5364016$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1608034$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Offenbacher, S.</creatorcontrib><creatorcontrib>Williams, R. C.</creatorcontrib><creatorcontrib>Jeffcoat, M. K.</creatorcontrib><creatorcontrib>Howell, T. H.</creatorcontrib><creatorcontrib>Odle, B. M.</creatorcontrib><creatorcontrib>Smith, M. A.</creatorcontrib><creatorcontrib>Hall, C. M.</creatorcontrib><creatorcontrib>Johnson, H. G.</creatorcontrib><creatorcontrib>Goldhaber, P.</creatorcontrib><title>Effects of NSAIDs on beagle crevicular cyclooxygenase metabolites and periodontal bone loss</title><title>Journal of periodontal research</title><addtitle>J Periodontal Res</addtitle><description>This investigation focuses on the changes in the concentrations of cyclooxygenase (CO) products present within the crevicular fluid in naturally‐progressing periodontitis in the beagle and the effects of various non‐steroidal anti‐inflammatory drugs (NSAIDs) on these metabolite levels and disease progression. Six groups of 5–6 beagles with periodontitis were followed for 6 months to determine the pretreatment rate of radiographic bone loss. At baseline, groups of animals were placed on soft chow to promote disease progression. Groups were treated with either placebo, three different formulations of systemic ibuprofen, systemic naproxen or topical flurbiprofen. During the 6‐month treatment phase, crevicular fluid (CF) samples and radiographs were taken at regular intervals. Radioimmunoassay of CF samples from untreated animals demonstrated a steady increase in prostaglandin E2 (PGE 2) over baseline values. At 1 month, CF‐PGE2 levels increased 2‐fold over baseline and, by 6 months, had reached a 5‐ to 6‐fold elevation. Crevicular fluid thromboxane B2 (CF‐TxB2) levels rapidly reached a 4‐ to 5‐fold peak over baseline at 1 month and subsequently dropped to a 2‐fold elevation for the remainder of the study. The rate of bone loss (BLOSS) in untreated animals increased 38% during the 6‐month period, as compared to baseline pretreatment BLOSS rates. Overall, there was a significant depression in the CF levels of both PGE2 and TxB2 in all NSAID‐treated groups. All NSAID treatments significantly retarded BLOSS, ranging from 21.0–36.9% of the control BLOSS rate. The topical application of flurbiprofen was as effective in depressing CF levels of PGE2 and TxB2 as systemic or sustained release formulations of other NSAIDs. The data further substantiate the concept that much of the BLOSS that occurs in periodontal disease is mediated by products of the cyclooxygenase pathway. Furthermore, CO activation represents a major regulatory step in bone destruction and may thereby serve as an important site for pharmacological modulation.</description><subject>Administration, Oral</subject><subject>Administration, Topical</subject><subject>Alveolar Bone Loss - drug therapy</subject><subject>Alveolar Bone Loss - metabolism</subject><subject>Analysis of Variance</subject><subject>Animals</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</subject><subject>Biological and medical sciences</subject><subject>bone loss</subject><subject>Bones, joints and connective tissue. Antiinflammatory agents</subject><subject>Cyclooxygenase Inhibitors - pharmacology</subject><subject>cyclooxygenase metabolites</subject><subject>Dentistry</subject><subject>Dinoprostone - metabolism</subject><subject>Dogs</subject><subject>Flurbiprofen - administration & dosage</subject><subject>Flurbiprofen - pharmacology</subject><subject>Gingival Crevicular Fluid - chemistry</subject><subject>Ibuprofen - administration & dosage</subject><subject>Ibuprofen - pharmacology</subject><subject>Medical sciences</subject><subject>Naproxen - administration & dosage</subject><subject>Naproxen - pharmacology</subject><subject>NSAIDs</subject><subject>Pharmacology. Drug treatments</subject><subject>Prostaglandins F - metabolism</subject><subject>Thromboxane B2 - metabolism</subject><issn>0022-3484</issn><issn>1600-0765</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkF1v0zAUhi0EGqXwE5AshLhLcOLYjrlAGlsZm6bxrSFxYfnjZErnxsVOof33uEpVrvGNbZ33POfoQehFRcoqn9fLsuKEFERwVlZS1uVoSMUFKbcP0OxYeohmhNR1QZu2eYyepLQk-c-FPEEnOdQS2szQz0XXgR0TDh2--Xp6eZ5fAzag7zxgG-F3bzdeR2x31oew3d3BoBPgFYzaBN-PkLAeHF5D7IMLw6g9NmEA7ENKT9GjTvsEzw73HH1_v_h29qG4_nhxeXZ6XVhGalEIYg1xWoOtnWtaB0Ja1nKm24bqqmKWAlhw0jXWaFIR1krWNaY1wEnTMU7n6NXEXcfwawNpVKs-WfBeDxA2SYlaSi4zbY7eTEEb83oROrWO_UrHnaqI2ptVS7XXp_b61N6sOphV29z8_DBlY1bg_rVOKnP95aGuk9W-i3qwfTrGGOVNRuXY2yn2p_ew-48F1NWXRU1EBhQToE8jbI8AHe8VF1QwdXtzoT5_uqI_3tFzdUv_AlGmpcc</recordid><startdate>199205</startdate><enddate>199205</enddate><creator>Offenbacher, S.</creator><creator>Williams, R. C.</creator><creator>Jeffcoat, M. K.</creator><creator>Howell, T. H.</creator><creator>Odle, B. M.</creator><creator>Smith, M. A.</creator><creator>Hall, C. M.</creator><creator>Johnson, H. G.</creator><creator>Goldhaber, P.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199205</creationdate><title>Effects of NSAIDs on beagle crevicular cyclooxygenase metabolites and periodontal bone loss</title><author>Offenbacher, S. ; Williams, R. C. ; Jeffcoat, M. K. ; Howell, T. H. ; Odle, B. M. ; Smith, M. A. ; Hall, C. M. ; Johnson, H. G. ; Goldhaber, P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5027-70cb0daaec2dd48de79c5865a843a115c3eeced9d4cba0105895f4b8be604f563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Administration, Oral</topic><topic>Administration, Topical</topic><topic>Alveolar Bone Loss - drug therapy</topic><topic>Alveolar Bone Loss - metabolism</topic><topic>Analysis of Variance</topic><topic>Animals</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</topic><topic>Biological and medical sciences</topic><topic>bone loss</topic><topic>Bones, joints and connective tissue. Antiinflammatory agents</topic><topic>Cyclooxygenase Inhibitors - pharmacology</topic><topic>cyclooxygenase metabolites</topic><topic>Dentistry</topic><topic>Dinoprostone - metabolism</topic><topic>Dogs</topic><topic>Flurbiprofen - administration & dosage</topic><topic>Flurbiprofen - pharmacology</topic><topic>Gingival Crevicular Fluid - chemistry</topic><topic>Ibuprofen - administration & dosage</topic><topic>Ibuprofen - pharmacology</topic><topic>Medical sciences</topic><topic>Naproxen - administration & dosage</topic><topic>Naproxen - pharmacology</topic><topic>NSAIDs</topic><topic>Pharmacology. Drug treatments</topic><topic>Prostaglandins F - metabolism</topic><topic>Thromboxane B2 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Offenbacher, S.</creatorcontrib><creatorcontrib>Williams, R. C.</creatorcontrib><creatorcontrib>Jeffcoat, M. K.</creatorcontrib><creatorcontrib>Howell, T. H.</creatorcontrib><creatorcontrib>Odle, B. M.</creatorcontrib><creatorcontrib>Smith, M. A.</creatorcontrib><creatorcontrib>Hall, C. M.</creatorcontrib><creatorcontrib>Johnson, H. G.</creatorcontrib><creatorcontrib>Goldhaber, P.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of periodontal research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Offenbacher, S.</au><au>Williams, R. C.</au><au>Jeffcoat, M. K.</au><au>Howell, T. H.</au><au>Odle, B. M.</au><au>Smith, M. A.</au><au>Hall, C. M.</au><au>Johnson, H. G.</au><au>Goldhaber, P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of NSAIDs on beagle crevicular cyclooxygenase metabolites and periodontal bone loss</atitle><jtitle>Journal of periodontal research</jtitle><addtitle>J Periodontal Res</addtitle><date>1992-05</date><risdate>1992</risdate><volume>27</volume><issue>3</issue><spage>207</spage><epage>213</epage><pages>207-213</pages><issn>0022-3484</issn><eissn>1600-0765</eissn><abstract>This investigation focuses on the changes in the concentrations of cyclooxygenase (CO) products present within the crevicular fluid in naturally‐progressing periodontitis in the beagle and the effects of various non‐steroidal anti‐inflammatory drugs (NSAIDs) on these metabolite levels and disease progression. Six groups of 5–6 beagles with periodontitis were followed for 6 months to determine the pretreatment rate of radiographic bone loss. At baseline, groups of animals were placed on soft chow to promote disease progression. Groups were treated with either placebo, three different formulations of systemic ibuprofen, systemic naproxen or topical flurbiprofen. During the 6‐month treatment phase, crevicular fluid (CF) samples and radiographs were taken at regular intervals. Radioimmunoassay of CF samples from untreated animals demonstrated a steady increase in prostaglandin E2 (PGE 2) over baseline values. At 1 month, CF‐PGE2 levels increased 2‐fold over baseline and, by 6 months, had reached a 5‐ to 6‐fold elevation. Crevicular fluid thromboxane B2 (CF‐TxB2) levels rapidly reached a 4‐ to 5‐fold peak over baseline at 1 month and subsequently dropped to a 2‐fold elevation for the remainder of the study. The rate of bone loss (BLOSS) in untreated animals increased 38% during the 6‐month period, as compared to baseline pretreatment BLOSS rates. Overall, there was a significant depression in the CF levels of both PGE2 and TxB2 in all NSAID‐treated groups. All NSAID treatments significantly retarded BLOSS, ranging from 21.0–36.9% of the control BLOSS rate. The topical application of flurbiprofen was as effective in depressing CF levels of PGE2 and TxB2 as systemic or sustained release formulations of other NSAIDs. The data further substantiate the concept that much of the BLOSS that occurs in periodontal disease is mediated by products of the cyclooxygenase pathway. Furthermore, CO activation represents a major regulatory step in bone destruction and may thereby serve as an important site for pharmacological modulation.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>1608034</pmid><doi>10.1111/j.1600-0765.1992.tb01670.x</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-3484 |
ispartof | Journal of periodontal research, 1992-05, Vol.27 (3), p.207-213 |
issn | 0022-3484 1600-0765 |
language | eng |
recordid | cdi_proquest_miscellaneous_72996984 |
source | Wiley-Blackwell Journals; MEDLINE |
subjects | Administration, Oral Administration, Topical Alveolar Bone Loss - drug therapy Alveolar Bone Loss - metabolism Analysis of Variance Animals Anti-Inflammatory Agents, Non-Steroidal - administration & dosage Anti-Inflammatory Agents, Non-Steroidal - pharmacology Biological and medical sciences bone loss Bones, joints and connective tissue. Antiinflammatory agents Cyclooxygenase Inhibitors - pharmacology cyclooxygenase metabolites Dentistry Dinoprostone - metabolism Dogs Flurbiprofen - administration & dosage Flurbiprofen - pharmacology Gingival Crevicular Fluid - chemistry Ibuprofen - administration & dosage Ibuprofen - pharmacology Medical sciences Naproxen - administration & dosage Naproxen - pharmacology NSAIDs Pharmacology. Drug treatments Prostaglandins F - metabolism Thromboxane B2 - metabolism |
title | Effects of NSAIDs on beagle crevicular cyclooxygenase metabolites and periodontal bone loss |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T19%3A01%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20NSAIDs%20on%20beagle%20crevicular%20cyclooxygenase%20metabolites%20and%20periodontal%20bone%20loss&rft.jtitle=Journal%20of%20periodontal%20research&rft.au=Offenbacher,%20S.&rft.date=1992-05&rft.volume=27&rft.issue=3&rft.spage=207&rft.epage=213&rft.pages=207-213&rft.issn=0022-3484&rft.eissn=1600-0765&rft_id=info:doi/10.1111/j.1600-0765.1992.tb01670.x&rft_dat=%3Cproquest_cross%3E72996984%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72996984&rft_id=info:pmid/1608034&rfr_iscdi=true |